The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases

Bone Marrow Transplantation

Volumn 23, Issue 9, 1999, Pages 861-865

  Rosales, F ^a   Peylan Ramu, N ^a   Cividalli, G ^a   Varadi, G ^a   Or, R ^a   Naparstek, E ^a   Slavin, S ^a   Nagler, A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic bone marrow transplantation; Busulfan, cyclophosphamide; Genetic diseases; Thiotepa

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; THIOTEPA;

ADOLESCENT; ADRENOLEUKODYSTROPHY; AGRANULOCYTOSIS; ALBERS SCHOENBERG DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DIARRHEA; FEMALE; GAUCHER DISEASE; GENETIC DISORDER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEREDITARY HEMOLYTIC ANEMIA; HLA MATCHING; HUMAN; HURLER SYNDROME; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG HEMORRHAGE; MALE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NIEMANN PICK DISEASE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SIBLING; SURVIVAL TIME; T CELL DEPLETION; T LYMPHOCYTE; THROMBOCYTOPENIA; VOMITING; WISKOTT ALDRICH SYNDROME;

EID: 0032945496     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701758     Document Type: Article

References (39)

1. Gatti RA, Allen HD, Meuwissen HJ et al. Immunological reconstitution of sex linked lymphophenic immunological deficiency. Lancet 1968; 2: 1366-1369.
2. Ballet JJ, Griscelli C, Coutris C et al. Bone marrow transplantation in osteopetrosis. Lancet 1977; 2: 1137-1140
3. Krivit W. A summary of 75 patients with storage diseases treated by bone marrow transplantation. In: Hobbs JR (ed). Correction of Certain Genetic Diseases by Transplantation. Cosent: London, 1992, pp 179-186.
4. Thomas ED, Buckner CD, Sander JE et al. Marrow transplantation for thalassemia. Lancet 1982; 2: 227-229.
5. Groth CG, Ringden O. Transplantation in relation to the treatment of inherited diseases. Transplantation 1984; 38: 319-327.
6. O'Reilly RJ, Brochstein J, Dinsmore R, Kirkpatrick D. Marrow transplantation for congenital disorders. Semin Hematol 1984; 21: 188-221.
7. Parkman R. The application of bone marrow transplantation to the treatment of genetic diseases. Science 1986; 232: 1373-1377.
8. Kapelushnik J, Slavin S, Nagler A et al. Bone marrow transplantation for correction of immune deficiency and genetic disorders. In: Xanthov M, Brucci R, Prindull G (eds). Neonatal Immunology and Haematology. Elsevier Science: Amsterdam, 1993, pp 195-197.
9. Cowan MJ. Bone marrow transplantation for the treatment of genetic diseases. Clin Biochem 1991; 24: 375-381
10. Lucarelli G, Polchi P, Galimberti M et al. Marrow transplantation for thalassemia following busulfan and cyclophosfamide. Lancet 1985; 1: 1355-1357.
11. Lucarelli G, Galimberti M, Polchi P et al. Marrow transplantation in patients with advanced thalassemia. New Engl J Med 1987; 316: 1050-1056.
12. Aversa F, Pelicci PG, Terenzi A et al. Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa. Bone Marrow Transplant 1991; 7 (Suppl. 2): 24.
13. Papadopoulos E, Carabasi M, Castro H et al. T-cell depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft versus host disease. Blood 1998; 91: 1093-1090.
14. Naparstek E, Or R, Nagler A et al. T cell depleted allogeneic bone marrow transplantation for acute leukemia using CAMPATH-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
15. Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoietic stern cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol 1993; 21: 913-921.
16. Down JD, Boudewijn A, Dilingh JH et al. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating agents. Br J Cancer 1994; 70: 611-616.
17. Down JD, Boudewijn A, Van Os R et al. Variations in radiation sensitivity and repair among different bone marrow hematopoietic stem cell subsets following fractionated irradiation. Blood 1995; 86: 122-127.
18. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancer after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
19. Burhouse S, Ramsay K, Pescovitz O et al. Growth in children following irradiation for bone marrow transplantation. Am J Ped Hem Oncol 1989; 11: 134-140.
20. Nagler A, Rosales F, Or R et al. The role of thiotepa in autologous bone marrow transplantation for acute leukemia. Leukemia Res 1998; 22: 991-995.
21. Terenzi A, Lubin J, Lapidot T et al. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 1990; 50: 717-720.
22. Przepiorka D, Ippoliti C, Khouri I et al. Allogeneic transplantation for advanced leukemia. Transplantation 1996; 62: 1806-1810.
23. Down JD, Westerhof GR, Boudewijn A et al. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant 1988; 21: 327-330.
24. Jeffrey A, Wilson V, Thein SL. Hypervariable minisatellite regions in human DNA. Nature 1985; 314: 67-73.
25. Wong Z, Wilson V, Patel I et al. Characterization of a panel of highly variable minisatellites cloned from human DNA. Ann Hum Genet 1987; 51: 269-288.
26. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273-275.
27. Bearman SI, Appelbaum FR, Buckner CD. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1588.
28. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-461.
29. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med 1990; 322: 417-421.
30. Sovillet G, Dutour A, Michel G. Bone marrow transplantation in thalassemia: the French GEGMO experience. 2nd Int Symp on Bone Marrow Transplantation. Pesaro, September 24-27, 1992 (Abstr. No. 17).
31. Slattery JT. Pharmacokinetics of busulfan in bone marrow ablation regimens. 2nd Int Symp on Bone Marrow Transplantation in Thalassemia. Pesaro, September 24-27, 1992 (Abstr. No. 28).
32. Lucarelli G, Clift RA, Galimberti M et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87: 2082-2088.
33. Lucarelli G. Bone marrow transplantation for thalassemia. J Int Med 1997; 242 (Suppl. 740): 49-52.
34. Dimopoulos M, Alexanian R, Przepiorka D et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous bone marrow or blood stem cell transplantation in high risk multiple myeloma. Blood 1993; 82: 2324-2328.
35. Przepiorka D, Dimopoulos M, Smith J et al. Thiotepa, busulfan and cyclophosphamide as a new preparative regimen for marrow transplantation: risk factors for early regimen related toxicity. Ann Hematol 1994; 68: 183-188.
36. Przepiorka D, Ippoliti C, Giralt S et al. A phase II study of high dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 449-453.
37. Przepiorka D, Madden T, Ippoliti C et al. Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol 1995; 37: 155-160.
38. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
39. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.